Authors | S | n | Age, mean, (range) | Treatment | Acute toxicities | Late toxicities | Survival |
---|---|---|---|---|---|---|---|
Song et al. | R | 82 | 76 (70–87) | Paclitaxel 135 mg/m2 J1-J29 | Leucopenia G4 10% | Esophageal stenosis 14,6% | mean PFS 18,2 m |
CDDP 30 mg/m2 J1 J3 - J29 J31 | Esophagitis G4 2% | radiation pneumonia 7% | 2 years PFS I-II 64% | ||||
RTE 60 Gy | Thrombopenia G4 1% | 2 years PFS III IV 21% | |||||
Su et al. | R | 96 | 73 (65–82) | 5FU | radiation pneumonia 15% | 1 year PFS 70,9 m | |
CDDP | 3 years PFS 52 m | ||||||
RTE 56–66 Gy Extensive or conventional | |||||||
Zhong et al. | RA | 79 | RTE 56–59.4 Gy | mean PFS 19,7 m | |||
Docetaxel 25 mg/m2 and CDDP 25 mg/m2 weekly | 1 year 78,5 / 61,2 | ||||||
post RTCT Docetaxel 60 mg/m2 and CDDP 75 mg/m2 | |||||||
Wang Jing et al. | R | 100 | 76 (70–88) | CRT 50.4–66 CDDP-5FU-Docetaxel 4 courses | Leucopenia 21% | radiation pneumonia 13% | mean PFS CRT 15 m |
Esophagitis 12% | 1 year PFS CRT 58% | ||||||
Pneumonia 10% | |||||||
Li et al. | R | 32 | 74 (70–90) | RT 50–60 Gy | Esophagitis G3–4: 25% | mean PFS 23 m | |
CT: Docetaxel weekly, CDDP-5FU, carboplatine-paclitaxel | |||||||
paclitaxel only, doxifluridine | |||||||
Zhonghua et al. | R | 89 | RT 60 Gy: extensive or conventional | Leucopenia G3 33% | overall 3 year survival 32,8% | ||
CT paclitaxel 125 mg/m2 CDDP 20 (or oxaliplatine) | |||||||
Uno et al. | R | 17 | 79 (75–85) | RT 50–60 Gy | Leucopenia G3 2% | median survival 9 months | |
CT CDDP 5FU | OS 1 year 39% | ||||||
Semrau et al. | R | 15 | 74.1 (70–85) | RT 63 Gy | radiation pneumonia 4 pts | OS 13,9 m | |
CDDP 20 mg/m2 and 5FU | Esophageal stenosis 9 pts | mean PFS 9,5 m | |||||
Anderson et al. | R | 25 | 77 (66–88) | RT 50.4 Gy | Leucopenia G4 16% | mean OS 35 months | |
CT 5FU Mitomycine | 1 year OS 80% | ||||||
Tougeron et al. | R | 109 | 74.4 (70–88) | RTE 50–55 Gy | Any G3 22% | median OS 15,2 +/− 3 m | |
5FU CDDP | one toxic death from sepsis | 2 year survival rates 35,5% | |||||
Tougeron et al. | R | 151 | mean 75 +/−4.1 | CRT 50–55 Gy, CDDP 5FU | Any G3 24.3% (mainly vomiting) | median OS 17,5 months | |
and neutropenia | 2-year survival 36,6% | ||||||
Xu et al. | R | 20 | 76 (70–88) | CRT 5FU CDDP | acute pneumonia G3–4: 5% | OS 17 months | |
CRT mean PFS 14 months | |||||||
Mak et al. | R | 28 | 79.5 (75–89) | CRT 50.4 Gy 5FU CDDP | any G4 38% | Esophageal G3 17% | median survival 12.4 months |
any G3 73.5% | no late pulmonary | ||||||
acute neutropenia G4: 23.5% | |||||||
one death from sepsis | |||||||
Tumori et al. | R | 57 | 69 | CRT | median survival 11,2 months | ||
Servagi et al. | RA | 30 | 85 (79–92) | CRT 50Gy CDDP only or Oxalipatin only | Dysphagia G4 13.3% | radiation pneumonia 10% | PFS at 1 year 40% |
Three year OS 22% |